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AbstrAct
Atovaquone is an FDA-approved anti-malarial drug, which first became 
clinically available in the year 2000. Currently, its main usage is for the treatment 
of pneumocystis pneumonia (PCP) and/or toxoplasmosis in immune-compromised 
patients. Atovaquone is a hydroxy-1,4-naphthoquinone analogue of ubiquinone, also 
known as Co-enzyme Q10 (CoQ10). It is a well-tolerated drug that does not cause 
myelo-suppression. Mechanistically, it is thought to act as a potent and selective 
OXPHOS inhibitor, by targeting the CoQ10-dependence of mitochondrial complex 
III. Here, we show for the first time that atovaquone also has anti-cancer activity, 
directed against Cancer Stem-like Cells (CSCs). More specifically, we demonstrate that 
atovaquone treatment of MCF7 breast cancer cells inhibits oxygen-consumption and 
metabolically induces aerobic glycolysis (the Warburg effect), as well as oxidative 
stress. Remarkably, atovaquone potently inhibits the propagation of MCF7-derived 
CSCs, with an IC-50 of 1 μM, as measured using the mammosphere assay. Atovaquone 
also maintains this selectivity and potency in mixed populations of CSCs and non-CSCs. 
Importantly, these results indicate that glycolysis itself is not sufficient to maintain the 
proliferation of CSCs, which is instead strictly dependent on mitochondrial function. 
In addition to targeting the proliferation of CSCs, atovaquone also induces apoptosis 
in both CD44+/CD24low/- CSC and ALDH+ CSC populations, during exposure to 
anchorage-independent conditions for 12 hours. However, it has no effect on oxygen 
consumption in normal human fibroblasts and, in this cellular context, behaves as an 
anti-inflammatory, consistent with the fact that it is well-tolerated in patients treated 
for infections. Future studies in xenograft models and human clinical trials may be 
warranted, as the IC-50 of atovaquone’s action on CSCs (1 μM) is >50 times less than 
its average serum concentration in humans.
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IntroductIon
Cancer Stem-like Cells (CSCs) are a sub-population 
of cancer cells that have been shown to be resistant to 
conventional chemo- and radio-therapy [1-4]. Residual 
CSCs left behind after clinical treatment are considered 
responsible for the re-growth of tumors and for their 
metastatic dissemination [5, 6]. Thus, much effort has 
been devoted to the development of agents that are 
able to specifically target CSCs. Most approaches have 
focused on the targeting of signaling pathways necessary 
for their survival, expansion or self-renewal, as well as 
CSC-specific cell surface markers [7-10]. Other strategies 
include the possibility to induce CSC differentiation or the 
targeting of the CSC “niche” [11-14].
CSCs are strictly dependent on mitochondrial 
biogenesis, as well as mitochondrial function, for their 
clonal expansion. We have shown that pharmacological 
inhibition of the formation of new mitochondria is 
sufficient to block breast CSCs. In this regard, we have 
demonstrated that treatment with doxycycline, an inhibitor 
of mitochondrial ribosomes, or with XCT790, an inverse 
agonist of Estrogen-Related Receptor α (ERRα), a 
cofactor of PGC1α that is required for the transcription 
of mitochondrial genes and mitochondrial biogenesis [15, 
16], was sufficient to reduce mammosphere formation 
and bona-fide CSC markers [17, 18]. Similarly, the 
antimicrobial tigecycline selectively killed acute myeloid 
leukemia stem cells, by inhibition of mitochondrial 
translation [19]. Moreover, treatment with oligomycin 
A, an inhibitor of the ATP synthase, greatly reduced 
mammosphere formation [20]. Similarly, metformin, 
which has complex I inhibitory effects, induced rapid 
apoptosis of pancreatic CSCs [21]. Salinomycin, an 
antibiotic that was recently identified as a selective 
inhibitor of CSCs [22] has been shown to reduce cell 
survival, at least partially, by impairing mitochondrial 
bioenergetic performance [23]. Finally, pyrvinium 
pamoate, an FDA-approved anti-parasitic agent, behaves 
as an OXPHOS inhibitor targeting mitochondrial complex 
II and efficiently prevents mammosphere formation in the 
nano-molar range, with an IC-50 of 50 nM [18]. However, 
pyrvinium pamoate is not absorbed efficiently from the 
gut, impeding its use for systemic anti-cancer therapy. 
Taken together, these studies provide a solid foundation 
and proof-of-concept for the new therapeutic strategy of 
targeting mitochondrial function to eradicate stem-like 
cancer cells. 
In an ongoing search for targeted, yet safe, 
mitochondrial inhibitors, we identified atovaquone, a 
complex III inhibitor, that was originally developed 
to block the mitochondrial respiration of Plasmodium 
falciparum and other protozoa [24]. Atovaquone is a 
safe, FDA-approved drug, used for malaria prevention, 
and for the prevention and treatment of pneumocystis 
pneumonia and toxoplasmosis in HIV patients [25, 
26]. Atovaquone can be administered alone as a liquid 
suspension (brand name Mepron) or in combination 
with Proguanil (brand name Malarone). Atovaquone is 
a highly lipophilic compound, with limited solubility in 
water. The bioavailability of atovaquone is dependent on 
its formulation and the diet, and its absorption is enhanced 
by high-fat food intake. Importantly, with current 
oral formulations, the average serum concentration of 
atovaquone in humans is > 50 μM. 
Atovaquone is an extremely non-toxic OXPHOS 
inhibitor. Remarkably, attempts to suicide by overdosing 
on atovaquone, by taking three to 42-fold the normal 
dose, resulted in few, if any, side effects. Atovaquone 
[trans-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4- 
naphthalene-dione] is a quinone that functions as a 
competitive inhibitor of co-enzyme Q10, specifically 
inhibiting the mitochondrial electron transport chain 
in mitochondria isolated from Plasmodium falciparum 
at the cytochrome bc1 complex (Complex III) [27, 28]. 
Consistent with these findings, atovaquone has been 
shown to depolarize malarial mitochondria, resulting in a 
loss of mitochondrial function [24].
However, atovaquone efficacy was never previously 
tested in CSCs. Here, we set out to evaluate if atovaquone 
is an inhibitor of mitochondrial function in cancer cells 
and if it can be used as a targeted agent for breast CSCs.
results
Atovaquone, a ‘safe’ oXPHos inhibitor that 
potently targets cancer stem cells
The aim of this study is to evaluate if atovaquone 
(Figure 1) is a potent inhibitor of mitochondrial function 
in cancer cells and if it can be used as a targeted agent for 
breast CSCs.
Towards this end, the metabolic profile of MCF7 
breast cancer cells treated with increasing concentrations 
of atovaquone was assessed using the Seahorse XF-e96 
analyzer. Atovaquone treatment markedly inhibits the 
mitochondrial respiration of MCF7 cells, with significant 
reductions in basal respiration, maximal respiration, 
and ATP levels (Figure 2). Moreover, atovaquone 
treatment increases aerobic glycolysis in MCF7 cells, 
with significant increases in glycolysis, glycolytic 
reserve, and glycolytic reserve capacity (Figure 3A-3E). 
The calculation of the Cell Energy Profile, obtained by 
plotting Oxygen Consumption Rates (OCR) against Extra-
Cellular Acidification Rates (ECAR), demonstrates that 
atovaquone shifts MCF7 cells from an oxidative state to a 
glycolytic state (Figure 3F).
To further characterize the mitochondrial function 
of MCF7 cells after treatment with atovaquone, MCF7 
cells were stained with various metabolic probes and 
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analyzed by FACS. Atovaquone decreases mitochondrial 
mass, as assessed with MitoTracker Deep-Red (Figure 
4A), and mitochondrial membrane potential, as assessed 
with MitoTracker Orange (Figure 4B). The ratio of 
mitochondrial membrane potential (MitoTracker Orange) 
versus mitochondrial mass (MitoTracker Deep-Red) 
was calculated, showing that atovaquone significantly 
decreases the mitochondrial membrane potential per 
mitochondria (Figure 4C). We next determined Reactive 
Oxygen Species (ROS) levels using the CM-H2DCFDA 
probe by FACS. Note that atoquavone increases ROS 
levels, as expected (Figure 4D). Taken together, these 
data are consistent with the fact that atovaquone acts as a 
mitochondrial inhibitor in cancer cells, greatly impairing 
mitochondrial respiration, with a compensatory increase 
in glycolysis.
We next asked if atovaquone functions as a 
mitochondrial inhibitor specifically for cancer cells, or if 
it affects all types of mammalian cells. To this end, we 
assessed the metabolic profile of normal human fibroblasts 
treated with atovaquone for 48 hours using the Seahorse 
XF-e96 analyzer. Surprisingly, atovaquone does not inhibit 
at all the basal respiration, maximal respiration, and ATP 
levels of normal human fibroblasts, but rather we observed 
a slight, but not significant, increase in mitochondrial 
respiration (Figure 5A-5D). The glycolytic profile of 
normal human fibroblasts treated with atovaquone was 
also assessed using the Seahorse XF-e96 analyzer. 
Significant increases in glycolysis, and glycolytic reserve 
were observed experimentally, indicating that atovaquone 
increases glycolysis in normal human fibroblasts (Figure 
6A-6E). Interestingly, in contrast to what we observed 
for MCF7 cancer cells, plotting of OCR against ECAR 
shows that atovaquone does not alter the metabolic state 
of normal human fibroblasts (Figure 6F). 
We next measured ROS levels in human fibroblasts 
treated with atovaquone. Note that atoquavone increases 
ROS levels (Figure 7A). An increase in ROS levels 
may induce the activation of stress-induced responses 
pathways, such as HIF pathway, and/or pro-inflammatory 
signaling, such as NFκB, which are potentially toxic 
Figure 2: Atovaquone treatment inhibits the mitochondrial respiration of McF7 breast cancer cells. The metabolic profile 
of MCF7 cell monolayers treated with atovaquone (5μM and 10 μM) for 48 hours was assessed using the Seahorse XF-e96 analyzer. A. The 
tracing of 3 independent experiments is shown. b., c., d. Significant reductions in basal respiration, maximal respiration, and ATP levels 
were observed experimentally. **p < 0.001, ****p < 0.00001, one-way ANOVA and Student’s t-test calculations.
Figure 1: Atovaquone: comparison with the structure 
of coQ10. Note that atovaquone A. is highly structurally-
related to CoQ10 b. and was first designed to target the MT-
CYB subunit of Cytochrome bc1 (mitochondrial complex III) in 
malarial parasites. 
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for cells. To monitor the activation of HIF and NFκB 
pathways after atovaquone treatment, we employed 
reporter fibroblasts carrying HIF- and NFκB-Luc 
reporter elements. Vehicle alone (DMSO) control cells 
were run in parallel. Surprisingly, atovaquone treatment 
decreases the activation of HIF and NFκB pathways in 
normal fibroblasts, in a dose-dependent manner (Figure 
7B-7C). These results indicate that atovaquone inhibits 
inflammatory or stress-induced responses, consistent with 
its safe use in the clinic. 
Having firmly established that atovaquone 
specifically inhibits mitochondrial respiration in MCF7 
cancer cells, but not in normal fibroblasts, we then 
asked if atovaquone could halt the propagation of the 
CSC population. To this end, MCF7 cells were plated 
for mammosphere assays in the presence of increasing 
concentrations of atovaquone or vehicle alone for 5 
days. Atovaquone dose-dependently inhibits MCF7 
mammosphere formation, with an IC-50 of ~1 μM 
(Figure 8A). To independently validate these results, 
Figure 3: Atovaquone treatment increases glycolysis in McF7 breast cancer cells. The glycolytic profile of MCF7 cell 
monolayers treated with atovaquone (5μM and 10 μM) for 48 hours was assessed using the Seahorse XF-e96 analyzer. A. The tracing of 3 
independent experiments is shown. b., c., d. Significant increases in glycolysis, glycolytic reserve, and glycolytic reserve capacity were 
observed experimentally. e. ECAR was also found increased. F. ECAR and OCR were plotted on the same graph. Note that atovaquone 
treatment (10 μM) shifts MCF7 cancer cells from an aerobic state to a glycolytic state. *p < 0.01, **p < 0.001, ***p < 0.0001, ****p < 
0.00001, ns not significant, one-way ANOVA and Student’s t-test calculations. 
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Figure 5: Atovaquone treatment does not affect the mitochondrial respiration of normal human fibroblasts. The 
metabolic profile of normal human fibroblast (hTERT-BJ1) monolayers treated with atovaquone (5μM and 10 μM) for 48 hours was 
assessed using the Seahorse XF-e96 analyzer. A. The tracing of 3 independent experiments is shown. b., c., d. Note that atovaquone does 
not significantly reduce basal respiration, maximal respiration, or ATP levels of normal human fibroblasts. ns, not significant; one-way 
ANOVA and Student’s t-test calculations.
Figure 4: Atovaquone treatment decreases mitochondrial mass and membrane potential, with an increase in ros 
levels. MCF7 cells were treated with atovaquone (5μM or 10 μM) for 48 hours, and stained with various metabolic probes and analyzed by 
FACS. A., b. Atovaquone decreases mitochondrial mass, as assessed with MitoTracker Deep-Red, and mitochondrial membrane potential, 
as assessed with MitoTracker Orange. c. The ratio of mitochondrial membrane potential (MitoTracker Orange) versus mitochondrial 
mass (MitoTracker Deep-Red) was calculated, showing that atovaquone significantly decreases mitochondrial membrane potential per 
mitochondria. d. ROS levels were determined using the CM-H2DCFDA probe by FACS. Note that atovaquone (10 μM) increases ROS 
levels, as expected. *p < 0.01, **p < 0.001, , ****p < 0.00001, one-way ANOVA and Student’s t-test calculations.
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the expression of CSC markers (CD24 and CD44) was 
analyzed by FACS. Notably, atovaquone pre-treatment 
dose-dependently decreases the CD44+/CD24-low cell 
population, which is considered to be the CSC population 
(Figure 8B). Next, we assessed ALDEFLUOR activity, 
an independent marker of CSCs, using MCF7 cells pre-
treated with atovaquone. A specific ALDH inhibitor 
(diethylaminobenzaldehyde - DEAB) was used for each 
sample, as a negative control. Note that atovaquone 
treatment significantly decreases the ALDH-positive 
cell population by 50% (Figure 8C). Thus, these results 
indicate that atovaquone treatment also induces apoptosis 
in MCF7-derived CSCs, during exposure to anchorage-
independent conditions (i.e., anoikis), for 12 hours. 
We next asked if atovaquone action is specific for 
CSCs, or if it affects the viability of the total cancer cell 
population or of normal human fibroblasts. To this end, 
cell viability was assessed on MCF7 cells and normal 
human fibroblasts (hTERT-BJ1) treated with atovaquone 
for 5 days. Interestingly, atovaquone treatment inhibits 
Figure 6: Atovaquone treatment increases glycolysis in normal human fibroblasts. The glycolytic profile of normal human 
fibroblast (hTERT-BJ1) monolayers treated with atovaquone (5μM and 10 μM) for 48 hours was assessed using the Seahorse XF96 
analyzer. A. The tracing of 3 independent experiments is shown. b., c., d. Significant increases in glycolysis, and glycolytic reserve were 
observed experimentally. e. ECAR was also found increased. F. ECAR and OCR were plotted on the same graph. Note that atovaquone 
treatment does not change the metabolic state of normal human fibroblasts. *p < 0.01, **p < 0.001, ***p < 0.0001, ****p < 0.00001, ns not 
significant, one-way ANOVA and Student’s t-test calculations. 
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MCF7 cell viability with an IC-50 of ~10 μM (Figure 9A), 
indicating that atovaquone preferentially inhibits CSCs 
(compare with Figure 8A), relative to the ‘bulk’ cancer 
cells. Thus, atovaquone is about 10 times more potent in 
the inhibition of CSCs propagation (IC-50 of ~1 μM). 
Moreover, atovaquone treatment only slightly inhibits 
normal human fibroblast viability, consistent with its safe 
use in humans (Figure 9B).
Finally, we asked if atovaquone could still target 
CSCs in a heterogeneous attached cell population, when 
they are mixed with the bulk of the cancer cells. To this 
end, MCF7 cells were pre-treated with atovaquone as 
monolayers for 2 days, and then cells were collected 
and re-plated on low-attachment plates in the absence of 
atovaquone, for mammosphere assays, or directly assessed 
for cell viability. Interestingly, atovaquone pre-treatment 
preferentially inhibits CSCs, in a dose-dependent fashion 
(~85% inhibition with 10 μM atovaquone) (Figure 10A), 
with more moderate effects on the viability of bulk cancer 
cells (only ~30% inhibition with 10 μM atovaquone) 
(Figure 10B). These results indicate that atovaquone is 
able to target CSCs also when they are in a heterogeneous 
attached cell population (IC-50 ~ 1 μM), when they are 
mixed with bulk cancer cells. 
Figure 7: Atovaquone treatment does not induce pro-inflammatory or stress-induced responses in human normal 
fibroblasts. A. ROS levels were measured in normal human fibroblasts treated with atovaquone (10 μM) or DMSO for 48 hours. Note 
that atovaquone increases ROS levels. b., c. The activation of HIF and NFκB pathways was monitored using Luc-reporter fibroblasts 
carrying HIF- and NFκB-Luc reporter elements. Luciferase assays were performed on cells treated with atovaquone (5μM and 10 μM) or 
DMSO control for 48 hours. Luminescence was normalized using SRB (total proteins), as a measure of cell viability. Note that atovaquone 
treatment decreases the activation of HIF (B) and NFκB (C) pathways in normal fibroblasts, in a dose-dependent manner. *p < 0.01, **p < 
0.001, ****p < 0.00001 evaluated with one-way ANOVA. 
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Figure 8: Atovaquone treatment inhibits McF7-derived cscs. A. MCF7 cells were plated for mammosphere assays in the 
presence of increasing concentrations of atovaquone or vehicle alone. Atovaquone dose-dependently inhibits MCF7 mammosphere 
formation efficiency (MFE) at 5 days, with an IC-50 of ~1 μM. *p < 0.05, **p < 0.00001, evaluated by Student’s t test. b. MCF7 cells 
were pre-treated with atovaquone (5μM and 10 μM) as monolayers for 48 hours and then re-plated on low-attachment plates in the 
absence of atovaquone, for anoikis assay for 12 hours. Expression of CSC markers (CD24 and CD44) was analyzed by FACS. Note that 
atovaquone pre-treatment dose-dependently decreases the CD44+/CD24-low cell population, which is considered the CSC population. c. 
MCF7 cells were pre-treated with atovaquone (5μM and 10 μM) as monolayers for 48 hours and then assessed for ALDEFLUOR activity, 
an independent marker of CSCs. Each sample was normalized using diethylaminobenzaldehyde (DEAB), a specific ALDH inhibitor, as 
negative control. C. The tracing of representative samples is shown. Note that atovaquone treatment decreases the ALDH-positive cell 
population by 50%. *p < 0.01, ****p < 0.00001 evaluated with one-way ANOVA. 
Figure 9: Atovaquone treatment preferentially inhibits cscs, with minor effects on the viability of normal human 
fibroblasts. MCF7 cells and normal human fibroblasts (hTERT-BJ1) were treated with atovaquone (5μM and 10 μM) for 5 days. Cell 
viability was assessed by SRB assay. A. Atovaquone treatment inhibits MCF7 cell viability with an IC-50 of ~10 μM, indicating that 
atovaquone preferentially inhibits CSCs (compare with Figure 8A), relative to the ‘bulk’ cancer cells. b. Atovaquone treatment slightly 
inhibits normal human fibroblast viability, consistent with its safe use in humans. ****p < 0.00001, ns not significant, evaluated with one-
way ANOVA. 
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Figure 11: Kaplan-Meier (K-M) analysis of the prognostic value of two components of mitochondrial complex III. 
Results of recurrence-free survival analysis (RFS) are shown, over nearly a 20-year period of follow-up, for two mitochondrial markers for 
all breast cancers taken as a single group (N = 2,609). Note that higher levels of these two mitochondrial markers are significantly associated 
with tumor recurrence. See the Methods section for further details of how the analysis was carried out. Similar results were obtained in other 
sub-types of breast cancer, including ER(+) and ER(-), and are included as Supplementary Figures S1 and S2. 
Figure 12: targeting oXPHos to eradicate cscs: repurposing 
atovaquone. The propagation of CSCs is thought to underpin the 
molecular and cellular basis of tumor recurrence, distant metastasis and 
resistance to chemo- and radio-therapy. Here, we suggest the use of a 
“safe” mitochondrial OXPHOS inhibitor to eradicate CSCs, which are 
addicted to mitochondrial function. More specifically, atovaquone (shown 
at right) inhibits mitochondrial complex III, by effectively competing with 
the binding of CoQ10 (shown at left).
Figure 10: Atovaquone pre-treatment preferentially inhibits cscs, with minor effects on the viability of bulk cancer 
cells. MCF7 cells were pre-treated with atovaquone (1μM and 10 μM) as monolayers for 2 days. Then, cells re-plated on low-attachment 
plates in the absence of atovaquone, for mammosphere assay for 5 days, or directly assessed for cell growth and viability. A. Atovaquone 
pre-treatment inhibits MCF7 cell mammosphere formation, in a dose-dependent fashion (~85% inhibition with 10 μM atovaquone). ***p < 
0.0001 evaluated by Student’s t test b. Under the same conditions, atovaquone has mild effects on the viability of bulk cancer cells (~30% 
inhibition of viability with 10 μM atovaquone). **p < 0.001 evaluated by Student’s t test. MFE: mammosphere forming efficiency. 
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Validation of the clinical relevance of 
mitochondrial complex III in human breast 
cancer patients, in both er(+) and er(-) epithelial 
sub-types
In order to assess the possible clinical relevance 
of mitochondrial complex III, we determined if different 
components of the complex show any prognostic value 
in human breast cancer patient cohorts, with long-term 
follow-up (approaching 20 years). These results are 
summarized in Tables 1 and 2. Corresponding Kaplan-
Meier (K-M) analysis curves are included in Figure 11, 
and as Supplementary Figures S1 and S2 (Panels A-I). 
More specifically, high mRNA expression levels 
of CYC1 (Cytochrome C1) and UQBP (Ubiquinol-
Cytochrome C Reductase Binding Protein), key 
components of complex III, are both associated with 
significantly reduced progression-free survival (i.e., higher 
tumor recurrence). Similar results were obtained in both 
ER(+) and ER(-) patients, as well as in ER(+) sub-types 
(luminal A and luminal B patients). Note that high levels 
of CYC1 and UQBP were also associated with progression 
in patients that received endocrine therapy, which is 
indicative of a clinical association with endocrine therapy-
resistance. 
Thus, in the future, elevated levels of expression 
of CYC1 and UQBP could be used to identify high-
risk ER(+) and ER(-) breast cancer patients that might 
benefit from treatment with atovaquone, a complex III 
inhibitor. In this context, CYC1 and UQBP could also 
be used as companion diagnostics, to guide the use of 
mitochondrially-targeted atovaquone therapy. 
dIscussIon
Atovaquone is an FDA-approved anti-parasitic drug 
that was first developed to target chloroquine-resistant 
malaria [25]. Currently, its major use is for managing 
pneumocystis pnenumonia (PCP) and toxoplasmosis 
infections in HIV-positive patients [26]. Structurally, 
atovaquone resembles CoQ10 and competitively inhibits 
its binding to the Cytochrome b subunit (MT-CYB) of 
mitochondrial complex III [27, 28]. As a consequence, 
here we explored the possibility that atovaquone could 
be repurposed for targeting mitochondrial complex III 
in breast cancer cells (summarized in Figure 12). To test 
this hypothesis, we first examined its metabolic effects 
on MCF7 cells, using the Seahorse XF-e96, to measure 
mitochondrial function and glycolysis. Our results directly 
show that atovaquone significantly inhibits oxygen 
consumption and ATP production in the low micromolar 
range. Moreover, atovaquone treatment significantly 
induced aerobic glycolysis (a.k.a., the Warburg effect). 
In this context, we demonstrated that atovaquone reduces 
both mitochondrial mass and membrane potential, 
but increased overall ROS production. Importantly, 
atovaquone potently inhibited the propagation of 
table 1: High cYc1 mrnA levels are associated with increased tumor recurrence, 
in both er(+) and er(-) breast cancer patients.
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CSCs, with an IC-50 of 1 μM, as measured using the 
mammosphere assay. Interestingly, this concentration is 
> 60 times lower than the average serum concentration 
achieved in patients. Remarkably, atovaquone treatment 
had little or no effect on normal human fibroblasts. 
When atovaquone suspension was administered in 
humans with food at the standard regimen of 750 mg twice 
daily, the average steady-state plasma concentration was 
21.0 ± 4.9 μg/mL, and the minimum plasma concentration 
was 16 ± 3.8 μg/mL [29]. It should be noted that in our 
experiments we have effectively ablated mammosphere 
formation with 10 μM atovaquone, which corresponds 
to 3.66 μg/mL. Thus, the clinically relevant, therapeutic 
plasma concentration of atovaquone is 5-times higher than 
the concentration that completely blocks the expansion of 
CSCs.
A thorough search of the literature revealed only 
one previous paper investigating the effects of atovaquone 
on cancer cell lines. Although mainly focused on the 
cytotoxicity and apoptosis-inducing activity of atovaquone 
derivatives, this report shows that atovaquone effectively 
inhibited the growth of Du145 prostate cancer cells, with 
an IC-50 of approximately 30 μM [30]. So, our current 
results are consistent with these overall findings. However, 
these authors did not evaluate the effects of atovaquone 
on CSCs.
Interestingly, it is well known that atovaquone 
binds directly to the Cytochrome b component of the 
Cytochrome bc1 complex, in the mitochondria of malarial 
parasites. This has been further verified by a mutational 
analysis and by determining the crystal structure of 
atovaquone bound to the Cytochrome b molecule, also 
known as MT-CYB [31, 32]. However, very little is 
known about the role of MT-CYB and the Cytochrome 
bc1 complex in cancer. 
Genetic evidence of a role for MT-CYB in cancer 
comes from studies on breast and colon cancers. A recent 
study used targeted sequencing of mitochondrial DNA in 
high-risk breast cancer patients negative for BRCA1/2 
mutations to provide new clinical evidence for MT-CYB 
variants as a risk factor for hereditary breast cancers [33]. 
Interestingly, they observed that two mitochondrial genes, 
namely MT-ATP6 (complex V) and MT-CYB (complex 
III) showed the highest number of variants in the high-
risk breast cancer patients. In further support of these 
findings, 4 homoplasmic and 6 heteroplasmic alterations 
were found in the mitochondrial DNA of human colon 
cancer cell lines; among these changes, a homoplasmic 
mutation in MT-CYB (G14804A) results in amino acid 
substitutions in highly conserved residues [34]. Two 
homoplasmic mutations in MT-CYB [G14985A (R80H) 
and T15572C (F276L)] were independently observed in 
another cohort of human colon cancer patients [35]. The 
fact that these mutations are homoplasmic indicates that 
they provide both a strong replicative and proliferative 
advantage. Interestingly, the two latter mutations in MT-
CYB did not result in any observable defects in OXPHOS, 
indicating that the mitochondria bearing these mutations 
table 2: High uQbP mrnA levels are associated with increased tumor 
recurrence, in both er(+) and er(-) breast cancer patients. 
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remained highly functional [35].
MT-CYB mutations have also been detected in 
human bladder carcinomas [36, 37]. For example, a 21-
bp in-frame deletion results in a loss of 7-amino acids 
in the MT-CYB protein product. Cells over-expressing 
this “activated mutant” of MT-CYB showed significant 
increases in cell proliferation and tumor growth, due to 
NFkB hyper-activation, increased oxygen consumption 
rates and resistance to apoptosis. This activated mutant of 
MT-CYB, specifically associated with bladder cancer, also 
functionally increased anchorage-independent growth and 
mitochondrial biogenesis, as well as mt-DNA content [36, 
37].
The Cytochrome bc1 complex contains two major 
subunits: Cytochrome b (MT-CYB) and Cytochrome c1 
(CYC1). Very little is known about the role of CYC1 
in cancer pathogenesis. However, silencing of CYC1 
(using an shRNA approach) in osteosarcoma cell lines 
effectively inhibits cellular proliferation, sensitizes the 
cells to apoptotic cell death and inhibits their ability to 
form tumors in xenograft models [38]. In their model 
system, the authors also demonstrated that CYC1 silencing 
significantly reduced mitochondrial complex III activity. 
Interestingly, several reports indicate that the 
expression levels of mitochondrial complex III subunits 
are altered in human breast cancers [39, 40]. For example, 
ubiquinol cytochrome c reductase (UQCRFS1) is 
amplified in a subset of breast cancers and is associated 
with higher tumor grade [40]. In addition, there appears 
to be a relationship between tamoxifen-sensitivity 
and complex III. More specifically, inhibition of 
mitochondrial complex III enhances the cytotoxicity of 
tamoxifen in MCF7 cells [41]. This synergy may stem 
from the observation that tamoxifen may act directly on 
mitochondria, as an inhibitor of complex III function [42].
Taken together with our current data, these results 
suggest that atovaquone treatment may be an effective 
new strategy for targeting the Cytochrome bc1 complex 
(especially MT-CYB and CYC1) in cancer, to prevent the 
proliferative expansion of CSCs and tumor growth. Further 
pre-clinical studies to test atovaquone efficacy are clearly 
warranted. In direct support of the idea that targeting 
mitochondrial complex III is a promising therapeutic 
strategy, Kwon, Jung and colleagues have developed a 
series of small molecules that successfully inhibited the 
activity of complex III (UQBP; ubiquinol-cytochrome c 
reductase binding protein) [43, 44]. Interestingly, these 
small molecules also dramatically reduced tumor growth 
in pre-clinical xenograft models (harboring U87MG 
glioblastoma cells), without showing any in vitro and in 
vivo toxicity. However, these novel molecules will need to 
undergo phase I clinical trials. 
In contrast, atovaquone is already FDA-approved 
and can immediately enter phase II clinical trails, 
potentially saving 10 years in development time and 
millions of dollars. Thus, the repurposing of atovaquone 
may be a more effective translational approach, to more 
rapidly bring mitochondrial complex III inhibitors to the 
clinic. 
MAterIAls And MetHods
Materials
MCF7 breast cancer cell lines were purchased from 
the ATCC. Human immortalized fibroblasts (hTERT-BJ1) 
were purchased from Clontech, Inc. Cells were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM), 
supplemented with 10% FBS (fetal bovine serum), 2 
mM GlutaMAX, and 1% Pen-Strep in a 37°C humidified 
atmosphere containing 5% CO2, unless otherwise noted. 
Gibco-brand cell culture media (DMEM/F12) was 
purchased from Life Technologies. Atovaquone was 
purchased from Sigma-Aldrich.
Seahorse XFe-96 metabolic flux analysis
Extracellular acidification rates (ECAR) and real-
time oxygen consumption rates (OCR) for MCF7 cells 
and fibroblasts treated with atovaquone were determined 
using the Seahorse Extracellular Flux (XFe-96) analyzer 
(Seahorse Bioscience, MA, USA) [17]. 10,000 cells per 
well were seeded into XFe-96 well cell culture plates, and 
incubated overnight to allow attachment. Then, cells were 
treated with atovaquone (5μM and 10 μM) for 48 hours. 
Vehicle alone (DMSO) control cells were processed in 
parallel. After 48 hours of incubation, cells were washed 
in pre-warmed XF assay media (or for OCR measurement, 
XF assay media supplemented with 10mM glucose, 1mM 
Pyruvate, 2mM L-glutamine and adjusted at 7.4 pH). 
Cells were then maintained in 175 µL/well of XF assay 
media at 37°C, in a non-CO2 incubator for 1 hour. During 
the incubation time, we loaded 25 µL of 80mM glucose, 
9µM oligomycin, and 1M 2-deoxyglucose (for ECAR 
measurement) or 10µM oligomycin, 9µM FCCP, 10µM 
rotenone, 10µM antimycin A (for OCR measurement), 
in XF assay media into the injection ports in the XFe-
96 sensor cartridge. Measurements were normalized 
by protein content (SRB or Bradford assay). Data set 
was analyzed by XFe-96 software and GraphPad Prism 
software, using one-way ANOVA and Student’s t-test 
calculations. All experiments were performed three times 
independently.
Mitochondrial staining
Mitochondrial activity was assessed with 
MitoTracker Orange (#M7510, Invitrogen), whose 
accumulation in mitochondria is dependent upon 
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membrane potential. Mitochondrial mass was determined 
using MitoTracker Deep-Red (#M22426, Invitrogen), 
localizing to mitochondria regardless of mitochondrial 
membrane potential. MCF7 cells were treated with 
atovaquone (5 μM and 10 μM) for 48 hours. Vehicle 
alone (DMSO) control cells were processed in parallel. 
After 48 hours, cells were incubated with pre-warmed 
MitoTracker staining solution (diluted in PBS/CM to a 
final concentration of 10 nM) for 30-60 minutes at 37°C. 
All subsequent steps were performed in the dark. Cells 
were washed in PBS, harvested, and re-suspended in 
300 μL of PBS/CM. Cells were then analyzed by flow 
cytometry using Fortessa (BD Bioscience). Data analysis 
was performed using FlowJo software.
ros staining
Reactive oxygen species (ROS) production was 
measured using CM-H2DCFDA (C6827, Invitrogen), 
a cell-permeable probe that is non-fluorescent until 
oxidation within the cell. Cells were treated with 10 μM 
atovaquone for 48 hours. Vehicle alone (DMSO) control 
cells were processed in parallel. After 48 hours, cells were 
washed with PBS, and incubated with CM-H2DCFDA 
(diluted in PBS/CM to a final concentration of 1 μM) for 
20 minutes at 37°C. All subsequent steps were performed 
in the dark. Cells were rinsed, harvested, and re-suspended 
in PBS/CM. Cells were then analyzed by flow cytometry 
using the Fortessa (BD Bioscience). ROS levels were 
estimated by using the mean fluorescent intensity of the 
viable cell population. The results were analyzed using 
FlowJo software (Tree star Inc.). 
Mammosphere culture
A single cell suspension was prepared using 
enzymatic (1x Trypsin-EDTA, Sigma Aldrich, #T3924), 
and manual disaggregation (25 gauge needle) [45]. Cells 
were plated at a density of 500 cells/cm2 in mammosphere 
medium (DMEM-F12/ B27/20ng/ml EGF/PenStrep) in 
non-adherent conditions, in culture dishes coated with 
(2-hydroxyethylmethacrylate) (poly-HEMA, Sigma, 
#P3932). Then, cells were treated with increasing 
concentrations of atovaquone (range 50 nM to 10 μM). 
Vehicle alone (DMSO) control cells were processed in 
parallel. Cells were grown for 5 days and maintained in 
a humidified incubator at 37°C. After 5 days for culture, 
spheres > 50 μm were counted using an eye piece 
graticule, and the percentage of cells plated which formed 
spheres was calculated and is referred to as percentage 
mammosphere formation, and was normalized to one (1 = 
100 %MFE). Similar results were also obtained when cells 
were seeded at a density of 200 cells/cm2.
cd44/cd24 analysis
1 x 105 MCF7 cells were treated with atovaquone 
(5 μM and 10 μM) for 48 hours in 6-well plates, grown 
as a monolayer. Then, cells were trypsinized and seeded 
in low-attachment plates in mammosphere media. After 
12 hours, MCF7 cells were spun down and incubated 
with CD24 (IOTest CD24-PE, Beckman Coulter) and 
CD44 (APC mouse Anti-Human CD44, BD Pharmingen 
cat.559942) antibodies for 15 minutes on ice. Cells were 
rinsed twice and incubated with LIVE/DEAD dye (Fixable 
Dead Violet reactive dye; Invitrogen) for 10 minutes. 
Samples were then analyzed by FACS (Fortessa, BD 
Bioscence). Only the live population, as identified by the 
LIVE/DEAD dye staining, was analyzed for CD24/CD44 
expression. Data were analyzed using FlowJo software. 
AldeFluor assay and separation of the AldH-
positive population by FAcs
ALDH activity was assessed in MCF7 cells after 
treatment with atovaquone (5μM and 10μM) or vehicle 
control. The ALDEFLUOR kit (StemCell Technologies, 
Vancouver, Canada) was used to isolate the population 
with high ALDH enzymatic activity by FACS (Fortessa, 
BD Bioscence). Briefly, 1 × 105 MCF7 cells were 
incubated in 1ml ALDEFLUOR assay buffer containing 
ALDH substrate (5μl/ml) for 40 minutes at 37°C. In each 
experiment, a sample of cells was stained under identical 
conditions with 30 μM of diethylaminobenzaldehyde 
(DEAB), a specific ALDH inhibitor, as negative control. 
The ALDEFLUOR-positive population was established 
in according to the manufacturer’s instructions and was 
evaluated in 2 × 104 cells. 
Pre-treatment of monolayers with atoquavone
After treatment with atovaquone in monolayers (1 
μM or 10 μM for 2 days), MCF7 cells were trypsinized 
and seeded for mammosphere cultures. In parallel, cells 
were assessed for cell viability or cell growth. Cell growth 
was quantitatively measured using an Automated Cell 
Counter (Biorad), and cell viability was assessed by 
labeling with Trypan blue (Sigma). 
srb assay
Cell viability was assessed by sulphorhodamine 
(SRB) assay, based on the measurement of cellular protein 
content. After treatment with atovaquone for 5 days in 96 
well plates, cells were fixed with 10% trichloroacetic acid 
(TCA) for 1 hour in cold room, and dried overnight at 
room temperature. Then, cells were incubated with SRB 
for 15 min, washed twice with 1% acetic acid, and air 
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dried for at least 3 hour. Finally, the protein-bound dye 
was dissolved in 10 mM Tris pH 8.8 solution and read 
using a plate reader at 540 nm.
Evaluation of HIF and NFκB signaling pathways
The Cignal Lenti reporter assay (Luc) system 
(Qiagen) was chosen for monitoring HIF- and NFκB-Luc 
pathway activity in fibroblasts, as we previously described 
[46, 47]. Luciferase assay (E1501, Promega) was 
performed in luciferase reporter hTERT-BJ1 cells treated 
with atovaquone. Briefly, 1 × 104 hTERT-BJ1 reporter 
cells were seeded in black-walled 96-well plates and then 
were treated with atovaquone (5μM and 10 μM) for 48 
hours. Vehicle alone (DMSO) control cells were run in 
parallel. Six replicates were used for each condition. After 
48 hours, luciferase assay was performed according to the 
manufacturer’s instructions. Light signal was acquired for 
2 minutes in photons/second in the Xenogen VivoVision 
IVIS Lumina (Caliper Life Sciences), and the results were 
analyzed using the Living Image 3.2 sofware (Caliper Life 
Sciences). Luminescence was normalized using SRB (total 
proteins), as a measure of cell viability.
statistical analysis
Statistical significance was measured using the 
analysis of variance (ANOVA) test or t-test. P ≤ 0.05 was 
considered significant and all statistical tests were two-
sided. 
Kaplan-Meier (K-M) analyses
To perform K-M analysis, we used an open-access 
online survival analysis tool to interrogate publically 
available microarray data from up to 2,609 breast cancer 
patients. This allowed us to determine their prognostic 
value. Biased and outlier array data were excluded 
from the analysis. Hazard-ratios were calculated, at the 
best auto-selected cut-off, and p-values were calculated 
using the logrank test and plotted in R. K-M curves were 
generated online using the K-M-plotter (as high-resolution 
TIFF files), using univariate analysis: http://kmplot.com/
analysis/index.php?p = service&cancer = breast. This 
allowed us to directly perform in silico validation of these 
mitochondrial biomarker candidates. 
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